Millie Nelson

The US Food and Drug Administration (FDA) has expanded GlaxoSmithKline’s approved Respiratory Syncytial Virus (RSV) vaccine Arexvy for use in adults through 50-59 years of age.

Independent advisors to the US Food and Drug Administration (FDA) have deemed the benefits of Eli Lilly’s Alzheimer’s drug donanemab (LY3002813) outweigh the risks.

Ipsen will use Marengo Therapeutics’ TriSTAR precision T-cell engager (TCE) platform to bolster selective Vβ T-cells to boost anti-tumor activity in difficult-to-treat ‘cold’ tumors.

When it comes to best practices for partnering, experts at BIO 2024 said companies should not change their collaboration strategy to fit market conditions.

Life Sciences partnering events company EBD Group discusses the importance of communication, education, and the trials and tribulations of organizing an event with sustainability in mind.

ScaleReady and Germfree discuss the need to rethink sustainability and move towards a more standardized and simplistic manufacturing model to ensure health equity can be achieved.

An expert from Alltrna discusses how transfer RNA (tRNA) can be used to treat rare diseases.

Eli Lilly has proposed a $364 million investment in the UK to launch the first Lilly Gateway Labs innovation space in Europe. Meanwhile, similar plans are underway in Beijing, China with two labs planned to support startups.

Q&A: Vetter Pharma SVP says both environmental and social sustainability are essential for pharmaceutical, biotechnology, and biomanufacturing companies.

Panelists at EBD's BIO Europe debated whether culture is the main reason US average funding rounds are double that across the pond.